Monday, February 13, 2017 8:25:40 AM
IMMU - 5.23 Pre-market now at 5.64/5.65.
Immunomedics Enters Agreement With Seattle Genetics for Exclusive Rights to Commercialize Sacituzumab Govitecan, Immunomedic to Receive $250M Upfront, Sell $15M of Stock to Seattle Genetics
Immunomedics Enters Agreement With Seattle Genetics for Exclusive Rights to Commercialize Sacituzumab Govitecan, Immunomedic to Receive $250M Upfront, Sell $15M of Stock to Seattle Genetics
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
